Does DHEA IVF Outcomes in Poor Responders?

Homerton University Hospital NHS Foundation Trust400 enrolled

Overview

This study is a RCT to examine whether DHEA is capable of improving results for poor responders to ovarian stimulation during IVF treatment

Poor responders to ovarian stimulation for IVF may be either predicted or evidenced from previous treatment. The ESHRE criteria for poor responders will be used to select candidates for this trial. A power calculation determined that 200 subjects should be recruited to each arm to receive either DHEA or placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

400

Conditions

Infertility, Female Poor Response to Ovulation Induction

Interventions

DehydroepiandrosteroneDRUG

75mg Dehydroepiandrosterone daily

PlaceboDRUG

Placebo

Eligibility

Sex: FEMALEMin age: 40 YearsMax age: 42 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 40 years * Markers for poor ovarian reserve (AMH \<7 pmol/L(\<1.1 ng/ml) and/or AFC\< 7) * Previous poor response to ovarian stimulation ( ≤3 oocytes with a conventional stimulation protocol) Exclusion Criteria: * Women \> 42 years * Women with premature ovarian failure / premature menopause (FSH\>40 U/L). Women already taking DHEA. * Patients with a known allergy to the trial drug or any of the active ingredients in the placebo.

Locations (1)

Homerton Fertility Centre

London, United Kingdom

Outcomes

Primary Outcomes

Clinical pregnancy rates

ultrasound confirmation of a foetus with a heartbeat

Time frame: at 6-8 weeks gestation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.